SK Biopharmaceuticals Deal History & Licensing Activity
SK Biopharmaceuticals is a large biotech headquartered in South Korea. Over the past three years, SK Biopharmaceuticals has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 5 active clinical trials, primarily in Neurology.
Deals (12mo)
3
Active Trials
5
Top Modality
Small Molecules
Focus Area
Neurology
SK Biopharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving SK Biopharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| 1ST-104 | 1ST Biotherapeutics | Other | Discovery | license | Sep 17, 2026 |
| 1ST-104 (c-Abl and LRRK2 dual inhibitor) | FirstBio | Small Molecules | Unknown | license | Sep 17, 2026 |
| Opakalim (Kv7 platform) | SK Biopharmaceuticals Co., Ltd. | Small Molecules | Phase 2 | license | Aug 26, 2026 |
SK Biopharmaceuticals Pipeline Focus
Therapeutic areas and modalities where SK Biopharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
SK Biopharmaceuticals Strategic Signals
Key indicators of SK Biopharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
SK Biopharmaceuticals Clinical Pipeline
SK Biopharmaceuticals has 5 active clinical trials across 4 development phases.
1
Phase 4
1
Phase 1
1
Phase 1/2
2
Phase 3
See How Your Asset Matches SK Biopharmaceuticals's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About SK Biopharmaceuticals Licensing & Deal Activity
SK Biopharmaceuticals is a large biotech company based in South Korea that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, SK Biopharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for SK Biopharmaceuticals include Neurology (4 deals and trials), Other (2 deals and trials), CNS Disorders (2 deals and trials), and Solid Tumors (1 deal and trial). In terms of modality, SK Biopharmaceuticals has shown particular interest in small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for SK Biopharmaceuticals and 700+ other biopharma companies. Use our Solidus to benchmark your asset against SK Biopharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.